Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8169843 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL18302566 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL346997 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL18682065 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL345860 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL25387433 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL9332338 | 0.98 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL5042482 | 0.98 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| Water SCHEMBL10648449 | 0.96 | HCRTR1 (0.34) | HCRTR1HCRTR2TMEM97SIGMAR1 | |
| SCHEMBL14793014 | 0.86 | HCRTR1 (0.33) | HCRTR1HCRTR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| CN-111148739-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| EP-3141235-A1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3-METHYLAZETIDINE-L -SULFONAMIDE | IP Gesellschaft für Management mbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2740458-B1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP GES FÜR MAN MBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-9221782-B2 | Compound | ASTRAZENECA AB (SE) | 2015-12-29 | — | — | US | disclosed |
| US-20140235606-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2014-08-21 | — | — | US | disclosed |
| EP-2593448-A1 | NEW CRISTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENY)METHYL)THIO]-6-{[(1R,2S)-2,3- DIHYDROXY-1-METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | AstraZeneca AB (SE) | 2013-05-22 | — | — | EP | disclosed |
| US-20130040926-A1 | NOVEL COMPOUND | ASTRAZENECA UK LIMITED | 2013-02-14 | — | — | US | disclosed |
| WO-2013008002-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-20120015927-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007748-A1 | NEW CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENY)METHYL)THIO]-6-{[(1R,2S)-2,3-DIHYDROXY-1- METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| US-7361775-B2 | Process for the preparation of (S)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2008-04-22 | — | — | US | disclosed |
| US-7361775-B2 | Process for the preparation of (S)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2008-04-22 | — | — | US | disclosed |
| EP-1673364-B1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2007-08-22 | — | — | EP | disclosed |
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | HCRTR1 4581/4885HCRTR2 4650/4885TMEM97 2176/4885 |
| US-20130040926-A1 | NOVEL COMPOUND | CXCR2, CXCR1, CCR5 | HCRTR1 645/4885HCRTR2 689/4885TMEM97 447/4885 |
| US-20160108023-A1 | Novel Compound | CXCR2, CXCR1, CCR5 | HCRTR1 645/4885HCRTR2 689/4885TMEM97 447/4885 |
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | AKR1C3, AK1, GAPDH | HCRTR1 1773/4885HCRTR2 2660/4885TMEM97 4333/4885 |
| US-20120015927-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | CXCR1, CXCR2, CCR2 | HCRTR1 337/4885HCRTR2 339/4885TMEM97 139/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | HCRTR1 4581/4885HCRTR2 4650/4885TMEM97 2176/4885 |
| US-20140235606-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | CXCR1, CXCR2, CCR2 | HCRTR1 318/4885HCRTR2 313/4885TMEM97 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.